Phase IIa Clinical Trial of 2cPA Started in Taiwan (Osteoarthritis)
October 1, 2022
The Phase IIa clinical trial of 2-carba cyclic phosphatidic acid
(2ccPA; synthetic compound, drug candidate) has begun in Taiwan.
This study targets osteoarthritis and aims to further evaluate the efficacy and safety of 2ccPA.
